Chuanlai Xu Selected Research

Mitochondrial Diseases (Mitochondrial Disease)

1/2019

Chiral Molecule-mediated Porous Cu xO Nanoparticle Clusters with Antioxidation Activity for Ameliorating Parkinson's Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chuanlai Xu Research Topics

Disease

13	Neoplasms (Cancer) 04/2022 - 01/2010
3	Poisoning 01/2022 - 12/2009
3	Infections 01/2021 - 03/2018
2	Alzheimer Disease (Alzheimer's Disease) 09/2021 - 01/2020
2	Virus Diseases (Viral Diseases) 04/2021 - 01/2021
1	Membranous Glomerulonephritis (Membranous Nephropathy) 02/2022
1	COVID-19 01/2022
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021
1	Thromboembolism 01/2021
1	Inflammation (Inflammations) 05/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2019
1	Parkinson Disease (Parkinson's Disease) 01/2019
1	Pathologic Processes 01/2018
1	Breast Neoplasms (Breast Cancer) 10/2015
1	Renal Insufficiency (Renal Failure) 01/2011

Drug/Important Bio-Agent (IBA)

3	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2018
2	AntigensIBA 04/2022 - 01/2021
2	AntibodiesIBA 02/2022 - 01/2022
2	Amyloid (Amyloid Fibrils)IBA 09/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 02/2016
2	GoldIBA 01/2019 - 10/2015
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 11/2017
2	Polymyxin B (Aerosporin)FDA LinkGeneric 12/2018 - 03/2018
2	Biological ProductsIBA 02/2016 - 12/2011
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 04/2022
1	Phospholipase A2 ReceptorsIBA 02/2022
1	HyoscyamineIBA 01/2022
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2022
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2022
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2022
1	Environmental Pollutants (Pollutants, Environmental)IBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	SynucleinsIBA 12/2021
1	Oxygen (Dioxygen)IBA 12/2021
1	Amyloidogenic ProteinsIBA 09/2021
1	Antiviral Agents (Antivirals)IBA 04/2021
1	Hepatitis B Core AntigensIBA 01/2021
1	Peptide Hydrolases (Proteases)FDA Link 01/2021
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2021
1	cuprous sulfide (copper(I) sulfide)IBA 01/2021
1	ParaquatIBA 05/2020
1	Therapeutic UsesIBA 12/2019
1	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2019
1	Polymyxins (Polymyxin)IBA 12/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 05/2017
1	Tumor Biomarkers (Tumor Markers)IBA 01/2017
1	SilverIBA 10/2015
1	Proteins (Proteins, Gene)FDA Link 10/2015
1	Mucin-1 (CA 15-3 Antigen)IBA 10/2015
1	Pharmaceutical PreparationsIBA 12/2011
1	Drug CarriersIBA 12/2011
1	melamineIBA 01/2011
1	cyanoginosin LR (microcystin LR)IBA 12/2009

Therapy/Procedure

4	Therapeutics 12/2021 - 01/2010
2	Photochemotherapy (Photodynamic Therapy) 12/2018 - 02/2016
2	Precision Medicine 05/2017 - 01/2010
1	Immunotherapy 04/2022
1	Photothermal Therapy 02/2016